TTK Healthcare

Which are the latest news on TTK Healthcare?

Why is TTK Healthcare Ltd. falling/rising?

As of 19-Jun, TTK Healthcare Ltd. is seeing its stock price rise to 930.15, up 5.56%, driven by strong sector performance, increased investor participation, and favorable moving averages. The stock has outperformed its sector and shows heightened investor confidence.

As of 19-Jun, TTK Healthcare Ltd. is experiencing a rise in its stock price, currently at 930.15, which reflects an increase of 49.0 or 5.56%. This upward movement can be attributed to several factors. Firstly, the stock outperformed its sector by 3.26% today, indicating strong relative performance. It opened with a gain of 2% and reached an intraday high of Rs 950.6, marking a significant increase of 7.88% during the trading session.<BR><BR>Additionally, there has been a notable rise in investor participation, with delivery volume on 18 June increasing by 141.57% compared to the 5-day average. This suggests heightened interest and confidence among investors. The stock is also trading above its 5-day, 20-day, 50-day, and 100-day moving averages, which typically signals positive momentum, although it remains below the 200-day moving average.<BR><BR>Overall, the combination of strong performance relative to the sector, increased investor activity, and favorable moving averages contributes to the rise in TTK Healthcare Ltd.'s stock price.

How big is TTK Healthcare?

As of 10th June, TTK Healthcare Ltd. has a market capitalization of 1,266.00 Cr, with recent Net Sales of 857.28 Cr and a Net Profit of 65.68 Cr. The company reported Shareholder's Funds of 1,065.05 Cr and Total Assets of 1,275.24 Cr for the latest annual period ending March 2025.

As of 10th June, TTK Healthcare Ltd. has a market capitalization of 1,266.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, TTK Healthcare reported Net Sales of 857.28 Cr and a Net Profit of 65.68 Cr.<BR><BR>For the latest annual period ending March 2025, the company had Shareholder's Funds of 1,065.05 Cr and Total Assets amounting to 1,275.24 Cr.

Who are in the management team of TTK Healthcare?

The management team of TTK Healthcare includes T T Raghunathan (Executive Chairman), S Kalyanaraman (Whole Time Director & Secretary), and several non-executive directors, both independent and non-independent, responsible for the company's strategic direction.

The management team of TTK Healthcare includes the following individuals:<BR><BR>1. **T T Raghunathan** - Executive Chairman<BR>2. **R K Tulshan** - Non-Executive & Non-Independent Director<BR>3. **K Shankaran** - Non-Executive & Non-Independent Director<BR>4. **S Kalyanaraman** - Whole Time Director & Secretary<BR>5. **Vandana R Walvekar** - Non-Executive & Independent Director<BR>6. **Girish Rao** - Non-Executive & Independent Director<BR>7. **S Balasubramanian** - Non-Executive & Independent Director<BR>8. **N Ramesh Rajan** - Non-Executive & Independent Director<BR>9. **V Ranganathan** - Non-Executive & Independent Director<BR>10. **T T Mukund** - Director<BR><BR>This team is responsible for overseeing the strategic direction and management of the company.

Who are the peers of the TTK Healthcare?

TTK Healthcare's peers include Godrej Industrie, DCM Shriram, Swan Corp, and others, with varying management risks and growth rates. TTK Healthcare has a 1-year return of -29.96%, better than Swan Corp's -33.01% but worse than Panth Infinity's 39.52%.

Peers: The peers of TTK Healthcare are Godrej Industrie, DCM Shriram, Swan Corp, Sindhu Trade, Balmer Lawrie, Dhunseri Vent., Empire Inds., Panth Infinity, and Aspinwall & Co.<BR><BR>Quality Snapshot: Excellent management risk is observed at DCM Shriram, while Average management risk is found at Swan Corp, Balmer Lawrie, TTK Healthcare, Dhunseri Vent., Empire Inds., Panth Infinity, Aspinwall & Co, and the rest. Below Average management risk is noted at Godrej Industrie, Sindhu Trade, and KCK Industries. Growth is Excellent at Godrej Industrie and Panth Infinity, Average at Balmer Lawrie, TTK Healthcare, Dhunseri Vent., Empire Inds., and the rest, and Below Average at DCM Shriram, Swan Corp, Sindhu Trade, and Aspinwall & Co. Capital Structure is Excellent at DCM Shriram, Sindhu Trade, Balmer Lawrie, TTK Healthcare, and Panth Infinity, Good at Dhunseri Vent. and Aspinwall & Co, Average at Empire Inds., and Below Average at Godrej Industrie, Swan Corp, and KCK Industries.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Panth Infinity at 39.52%, while the peer with the lowest is Swan Corp at -33.01%. TTK Healthcare's 1-year return is -29.96%, which is higher than Swan Corp's but lower than Panth Infinity's. Additionally, peers such as Swan Corp, Balmer Lawrie, Dhunseri Vent., and TTK Healthcare have negative six-month returns.

What does TTK Healthcare do?

TTK Healthcare Ltd. is a micro-cap company involved in pharmaceuticals, consumer products, medical devices, and foods, with a market cap of INR 1,266 Cr. As of March 2026, it reported net sales of 218 Cr and a net profit of 22 Cr.

Overview:<BR>TTK Healthcare Ltd. operates in the diversified industry as a micro-cap company, focusing on pharmaceuticals, consumer products, medical devices, foods, and protective devices.<BR><BR>History:<BR>TTK Healthcare Limited was incorporated in May 1958 as Orient Pharma and was later renamed TTK Pharma in November 1981. The latest quarterly results reported net sales and net profit for March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 218 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 22 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 1,266 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 18.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 1.10% <BR>Debt-Equity: -0.55 <BR>Return on Equity: 6.17% <BR>Price to Book: 1.15 <BR><BR>Contact Details:<BR>Address: 6 Cathedral Road, Chennai Tamil Nadu: 600086 <BR>Tel: 91-44-28116106-28116110 <BR>Email: info@ttkhealthcare.com <BR>Website: http://www.ttkhealthcare.com

Are TTK Healthcare Ltd. latest results good or bad?

TTK Healthcare Ltd.'s latest results show strong revenue growth and a significant profit increase, but declining operating margins and reliance on non-operating income raise concerns about sustainability, making the overall outlook mixed.

TTK Healthcare Ltd.'s latest results present a mixed picture. On the positive side, the company reported a net profit of ₹21.76 crores for Q4 FY26, which is a significant increase of 106.65% quarter-on-quarter and a 34.73% rise year-on-year. Additionally, revenue grew by 14.51% year-on-year to ₹217.98 crores, indicating strong top-line momentum.<BR><BR>However, there are notable concerns regarding the company's operating margins. The operating margin has decreased to 5.06%, down from 6.31% in the same quarter last year, reflecting rising cost pressures that the company has struggled to manage. This decline in margin raises questions about the sustainability of profitability, especially since a substantial portion of the profit before tax, approximately 60.18%, came from other income rather than core operations.<BR><BR>In summary, while TTK Healthcare has shown impressive revenue growth and profit recovery, the deterioration in operating margins and reliance on non-operating income are significant red flags. This combination suggests that the overall results could be viewed as concerning, despite some positive indicators.

Should I buy, sell or hold TTK Healthcare Ltd.?

When is the next results date for TTK Healthcare Ltd.?

The next results date for TTK Healthcare Ltd. is 30 May 2026.

The next results date for TTK Healthcare Ltd. is scheduled for 30 May 2026.

Is TTK Healthcare technically bullish or bearish?

As of December 3, 2025, the technical trend has shifted to a moderate bearish stance, driven by bearish MACD readings, Bollinger Bands, and daily moving averages, despite mixed signals from the RSI and KST, with the stock underperforming against the Sensex.

As of 3 December 2025, the technical trend has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include the bearish MACD readings on both the weekly and monthly time frames, bearish Bollinger Bands, and a bearish daily moving average. The RSI shows no signal on the weekly but is bullish on the monthly, indicating mixed signals. The KST is mildly bullish weekly but bearish monthly, while the OBV is mildly bearish weekly and mildly bullish monthly, adding to the overall bearish sentiment. The stock has underperformed significantly against the Sensex over multiple time frames, further supporting the bearish outlook.

How has been the historical performance of TTK Healthcare?

TTK Healthcare has shown steady growth in net sales and profit from Mar'21 to Mar'25, with net sales increasing from 636.53 Cr to 801.49 Cr and profit before tax rising from 24.84 Cr to 108.33 Cr. However, the company has faced challenges with rising costs and negative cash flow from operating activities.

Answer:<BR>The historical performance of TTK Healthcare shows a steady growth in net sales and profit over the years, with significant fluctuations in certain metrics.<BR><BR>Breakdown:<BR>TTK Healthcare's net sales have increased from 636.53 Cr in Mar'21 to 801.49 Cr in Mar'25, reflecting a consistent upward trend. Total operating income followed a similar trajectory, rising from 645.77 Cr in Mar'20 to 801.49 Cr in Mar'25. The company faced rising raw material costs, which increased from 98.92 Cr in Mar'21 to 195.34 Cr in Mar'25, while the purchase of finished goods also grew from 148.77 Cr to 186.95 Cr in the same period. Operating profit (PBDIT) showed fluctuations, peaking at 106.07 Cr in Mar'25 after a dip in Mar'22. Profit before tax rose significantly from 24.84 Cr in Mar'22 to 108.33 Cr in Mar'25, leading to a profit after tax of 81.66 Cr in Mar'25, up from 18.51 Cr in Mar'22. The company's total assets increased from 427.04 Cr in Mar'20 to 1,275.24 Cr in Mar'25, while total liabilities also rose, reflecting a growth in both equity capital and reserves. Cash flow from operating activities has been negative in recent years, indicating challenges in cash generation, although cash flow from investing activities remained positive. Overall, TTK Healthcare has demonstrated growth in sales and profitability, despite facing challenges with costs and cash flow management.

Is TTK Healthcare overvalued or undervalued?

As of July 28, 2025, TTK Healthcare is considered undervalued with an attractive valuation grade, a PE ratio of 25.50, and competitive financial metrics, making it a potential buying opportunity despite recent underperformance compared to the Sensex.

As of 28 July 2025, TTK Healthcare's valuation grade has moved from fair to attractive, indicating a positive shift in its market perception. The company is currently considered undervalued, with a PE ratio of 25.50, an EV to EBITDA of 29.89, and a Price to Book Value of 1.69. In comparison to its peers, TTK Healthcare's PE ratio is lower than Sun Pharma's 35.57 and Divi's Lab's 79.83, both of which are categorized as expensive, while it is more favorable than Cipla's attractive PE of 23.53.<BR><BR>TTK Healthcare's financial metrics suggest it is positioned well within its industry, especially with a PEG ratio of 2.04, which is competitive against peers like Dr. Reddy's Labs at 9.35. Despite recent stock performance trailing the Sensex, particularly with a year-to-date return of -9.92% compared to the Sensex's 3.52%, the overall valuation indicates that TTK Healthcare presents a buying opportunity for investors looking for growth in the diversified healthcare sector.

Who are the top shareholders of the TTK Healthcare?

The top shareholders of TTK Healthcare are primarily its promoters, with T T Krishnamachari & Co. holding 67.46%. Other notable shareholders include Jupiter India Fund at 1.52% and individual investors with a combined 16.01%.

The top shareholders of TTK Healthcare are primarily its promoters, with T T Krishnamachari & Co. holding the largest share at 67.46%, represented by its partners Mr. T T Jagannathan and Mr. T T Raghunathan. Other notable shareholders include Jupiter India Fund, which holds 1.52%, and individual investors collectively owning 16.01%. Additionally, there are four mutual fund schemes that hold a combined 0.04%, and nine foreign institutional investors (FIIs) with a total holding of 1.89%.

Has TTK Healthcare declared dividend?

TTK Healthcare Ltd. has declared a 100% dividend, amounting to ₹10 per share, with an ex-date of July 16, 2024. While the recent total returns show declines in the short term, the company has experienced significant growth over the longer term.

TTK Healthcare Ltd. has declared a 100% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 100%<BR>- Amount per share: 10<BR>- Ex-date: 16 Jul 24<BR><BR>Dividend Yield: 0.81%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -21.3%, the dividend return was 0%, resulting in a total return of -21.3%.<BR><BR>Over the past year, the price return was -14.86%, the dividend return was 0.66%, leading to a total return of -14.2%.<BR><BR>In the 2-year period, the price return was -3.25%, the dividend return was 1.58%, culminating in a total return of -1.67%.<BR><BR>For the 3-year period, the price return was 66.56%, the dividend return was 4.22%, resulting in a total return of 70.78%.<BR><BR>In the last 4 years, the price return was 81.28%, the dividend return was 5.44%, which brought the total return to 86.72%.<BR><BR>Over the past 5 years, the price return was 187.39%, the dividend return was 8.95%, leading to a total return of 196.34%.<BR><BR>Overall, TTK Healthcare has declared a substantial dividend, but the recent total returns indicate a mixed performance, with significant growth over the longer term despite recent declines in shorter periods.